First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
This video was recorded during the AHA Scientific Sessions 2022 in Chicago, IL, USA.
Prof. Julian D. Gillmore, MD, PhD - London, UK
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: